Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05891587 · ClinicalTrials.gov registry record · Phase 2
Semaglutide Therapy for Alcohol Reduction - Tulsa
A Phase 2 study, sponsored by Oklahoma State University Center for Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT05891587 is a Phase 2 study that has completed, run by Oklahoma State University Center for Health Sciences. The registered enrollment target is 80 participants.
The verdict
NCT05891587, a Phase 2 study, has completed, sponsored by Oklahoma State University Center for Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.
Interventions
- DRUG Placebo
- DRUG Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-07-07 |
| Est. Completion | 2025-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05891587
The ClinicalTrials.gov registry entry for NCT05891587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oklahoma State University Center for Health Sciences, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05891587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05891587 about?
NCT05891587 is a clinical study titled "Semaglutide Therapy for Alcohol Reduction - Tulsa". The purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.
What is the current status of trial NCT05891587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-07-07. Estimated completion is 2025-10-01.
What interventions are being tested in trial NCT05891587?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT05891587?
This trial is sponsored by Oklahoma State University Center for Health Sciences, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.